Zentalis Pharmaceuticals (ZNTL) Return on Capital Employed (2020 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Return on Capital Employed of 61.51% for Q1 2026, down 224.0% year-over-year from 49.61% in Q1 2025, and down 9.32% quarter-over-quarter from 56.27% in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Return on Capital Employed (2020 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 61.51% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 224.0% year-over-year to 61.51%; the TTM figure through Mar 2026 stood at 61.51% (down 224.0% YoY), while the FY2025 annual figure was 47.3%, down 367.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 61.51%, down from 56.27% in the prior quarter.
- The five-year high for Return on Capital Employed was 45.25% in Q3 2022, with the low at 61.51% in Q1 2026.
- The 5-year median for Return on Capital Employed is 53.04% (2022), against an average of 53.45%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed soared 1992 bps in 2022, then slumped 1239 bps in 2023.
- Zentalis Pharmaceuticals' Return on Capital Employed stood at 47.59% in 2022, then fell by 26 bps to 59.98% in 2023, then rose by 18 bps to 49.31% in 2024, then dropped by 14 bps to 56.27% in 2025, then fell by 9 bps to 61.51% in 2026.
- Business Quant data shows ZNTL's Return on Capital Employed at 61.51% in Q1 2026, 56.27% in Q4 2025, and 54.67% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | -78.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -78.02% |
| Mar 31, 2026 | -61.51% |
| Dec 31, 2025 | -56.27% |
| Sep 30, 2025 | -54.67% |
| Jun 30, 2025 | -55.64% |
| Mar 31, 2025 | -59.27% |
| Dec 31, 2024 | -49.31% |
| Sep 30, 2024 | -50.27% |
| Jun 30, 2024 | -48.17% |
| Mar 31, 2024 | -51.89% |
| Dec 31, 2023 | -59.98% |
| Sep 30, 2023 | -52.02% |
| Jun 30, 2023 | -54.57% |
| Mar 31, 2023 | -51.17% |
| Dec 31, 2022 | -47.59% |
| Sep 30, 2022 | -45.25% |
| Jun 30, 2022 | -53.04% |
| Mar 31, 2022 | -57.96% |
| Dec 31, 2021 | -54.02% |
| Sep 30, 2021 | -65.16% |